A novel series of sanguinarine (SA) derivatives were synthesized and firstly evaluated as anti-NSCLC agents. The SARs studies suggested that the CN+ bond was critical for anti-cancer activity and the C6-position was tolerated to be substituted by hydrophilic groups and CN.